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ABSTRACT

RACIAL AND ETHNIC MINOTIRY GROUPS ARE UNDER-REPRESENTED
AND UNDER-REPORTED IN GUIDELINE-INFORMING HEART FAILURE
CLINICAL TRIALS

Gerardo Gamino
Physiology and Developmental Biology Department
Bachelor of Sciences

Heart failure (HF) is a common cause of morbidity and mortality in the
United States (U.S.) that may disproportionately affect certain racial/ethnic
groups.1,2 Compared with White individuals, HF may affect Black individuals at a
younger age with less favorable prognosis, and this excess risk may be partially
explained by differences in HF risk factor burden.3 It is crucial for guideline
informing HF clinical trials to adequately reflect the racial/ethnic diversity in the
population. We assessed the extent of reporting and representation of
race/ethnicity in HF clinical trials referenced in the 2013 American College of
Cardiology (ACC) Foundation/ American Heart Association (AHA) Guideline for
the Management of Heart Failure and the 2017 ACC/AHA/Heart Failure Society
of America (HFSA) Focused Update.2,4 All randomized clinic trials referenced in
these guidelines were included. The prevalence of reporting of race/ethnicity, the
proportions of racial/ethnic subgroups enrolled, and subgroup analysis based on
intervention type – pharmacologic, device, and other – were evaluated. A total of
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265 trials (547,353 subjects) were included in the study which were published
between 1950 and 2018. Among these, only 99 trials reported any race/ethnicity
(37.4%), 97 reported white race (36.6%), 57 reported Black race (21.5%), 15
reported Hispanic ethnicity (5.7%), and 24 reported Asian race (9.1%). In trials
reporting white, black, Hispanic, and Asian race/ethnicity respectively, 77.8% (n =
248,321/319,070) of patients were white, 12.3% (n = 29,353/239,192) of patients
were black, 11.0% (n = 8,374/76,099) of patients were Hispanic, and 9.7% (n =
15,063/155,577) of patients were Asian. Stratification by intervention type
demonstrated that no device trials referenced in the guidelines report Asian race
of Hispanic ethnicity, and just a single trial reported Black race. Clinical trials that
dictate clinical care of patients with HF through informing contemporary
ACC/AHA HF guidelines under-represent Black and Hispanic populations.
Additionally, two-thirds of trials fail to report any race/ ethnicity at all. Guideline
and practice-informing clinical trials need to improve the representation of
minority populations to provide clinicians with generalizable data.
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INTRODUCTION
Among cardiovascular diseases, heart failure (HF) is the number one
cause of cardiovascular related hospitalization in the U.S., and it is the fifth
leading cause of hospitalization overall.5 This is problematic for the increasing
population of racial/ethnic minority groups who carry an uneven burden of this
disease. African Americans are one such group that has a higher incidence rate
of congestive HF.1 From 2013-2016, the prevalence of HF in males older than 20
years for Blacks/African Americans and Hispanics was 3.5% and 2.5%
respectively.6 In the MESA study, Blacks had the highest risk of developing HF
followed by Hispanics and Whites at 4.6, 3.5, 2.4 per 1000 person-years,
respectively.7 These higher rates have been connected to higher comorbidity
rates of hypertension, diabetes mellitus, and obesity linked to poverty and other
environmental factors.1,6
The Federal Drug Administration’s (FDA) Office of Minority Health has
recognized the disproportionate effect cardiovascular diseases have on ethnic
minorities and have organized a dedicated effort to improve the production of
medical products that represent the general population.8 This disparity can be
attributed in part to lifestyle and socioeconomic factors, however differences in
patients can also result from genetic variants that are more common in specific
subpopulations. Regarding variations between races and ethnicities, there are
many documented differences in drug metabolism, toxicity in chemotherapy,
immunosuppressants, and cardiovascular drugs.8 Proper representation of
diverse patient populations in clinical trials will promote proper inclusion of
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genetic variation across racial and ethnic groups, thereby improving the
heterogeneity of trial results.
Although there is a general push to increase the amount of racial/ethnic
minority patients included in clinical trials, there are several reports that conclude
that racial/ethnic minorities are underrepresented in clinical trials. HF clinical
trials are no exception to this problem as elderly patients, women, and racial
minority groups have been found to be underrepresented in HF clinical trials. 9
Apart from hindering the generalizability of trial results, the lack of proper
representation affects the clinical practice guidelines that use trials as their
primary evidence base. Clinical trials used to formulate standard guidelines for
the management of disease have an added degree of importance because of
their impact on the treatment of patients.
The African American HF trial (A-HeFT) took into account a specific
variation among African American HF patients and found a 40% reduction in allcause mortality and a 33% reduction in first hospitalizations in this population by
using a certain combination of therapeutic agents.10 This trial helped shape a
portion of the 2013 ACC/AHA HF guidelines and it exemplifies the importance of
clinical trials that include sufficient racial and ethnic minorities in their patient
populations. However, if clinical trials do not adequately represent these groups,
then clinical practice guidelines will not have the needed evidence to properly
outline the best management for specific populations.
As mentioned above, there is a general lack of representation of
racial/ethnic minorities in clinical trials, and this project hypothesizes that there is
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an underrepresentation and underreporting of racial/ethnic minorities in the HF
clinical trials cited in clinical guidelines compared to U.S. Census and HF
proportions.
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METHODS
Data Collection
Two authors (J.P, G.G) performed a review of the 2013 ACC/AHA HF
guidelines and the 2017 focused update to identify all cited randomized clinical
trials. Only primary manuscripts, the first full report of the primary outcomes of a
trial, were included in the review regardless of trial size. Secondary reports,
including follow-up studies, meta-analyses, and observational studies were
excluded. The range of publications dates spanned from 1950 to 2018 which was
selected to encompass all clinical trials cited in the HF guidelines. The following
data were abstracted from the manuscripts: (1) trial name; (2) year of publication;
(3) journal name; (4) type of intervention (drug, device, procedure, laboratory
test, or other); (5) first year of enrollment (6) total sample size; (7) funding
source; and (8) race and ethnicity (if reported). When examining the manuscripts
and their associated supplemental materials (figures and tables) for the reporting
of enrollment by race/ethnicity, the following racial/ethnic groups were included:
White, Black, Hispanic/Latinx, and Asian. Racial/ethnic groups were defined
according to the racial/ethnic categories described in the Revisions to the
Standards for the Classification of Federal Data on Race and Ethnicity. 11 White
race was defined as a person having origins in any of the original peoples of
Europe, the Middle East, or North Africa. Black race was defined as a person
having origins in any of the black racial groups of Africa. Hispanic ethnicity was
defined as a person of Cuban, Mexican, Puerto Rican, South or Central
American, or other Spanish culture or origin. Asian race was defined as a person
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having origins in any of the original peoples of the Far East, Southeast Asia, or
the Indian subcontinent. Patients were divided into these categories according to
the information reported in the trials themselves. Due to reporting limitations,
White and Black categories included subjects with (“non-Hispanic”) or without an
indicated ethnicity (ie “White” or “Black”).
Statistical Comparison
For each racial/ethnic group, we determined the median enrollment rates
across trials that reported each race/ethnicity. This was compared with U.S.
Census proportions (2018) and estimates of race/ethnicity specific prevalent HF
population proportions (2016). We then pooled all subjects and determined
whether proportions differed significantly from that expected based on U.S.
Census proportions or HF proportions using two-proportion z-tests. Trials were
stratified by intervention type to determine the number of trials reporting
race/ethnicity by trial type. Further demographic descriptions, including sex and
age were not included in the study because past research has established the
underrepresentation of women and the elderly in HF trials.9 Other races such as
Native American, Alaskan Native, Hawaiian or pacific Islander were not included
in the study because of insufficient and inconsistent reporting of these categories
in included trials. Data on the levels of awareness for clinical trials among
racial/ethnic groups, access to health care services, level of education, and
disease severity were not included in the study as only data included in the trials
was considered.
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RESULTS
Reporting and Representation
We identified 265 trials (547,353 subjects total, median trial size 448
subjects) published between 1950 and 2018. Among these, 99 trials reported any
race/ethnicity (37.4%). White race, Black race, Hispanic/Latinx ethnicity, and
Asian race were reported in 97 (36.6%), 57 (21.5%), 15 (5.7%), and 24 trials
(9.1%), respectively. Compared to U.S. Census data, we found an
overrepresentation of White subjects (Trial median: 85.6%, Census: 72.2%, HF
population: 61.8%) and underrepresentation of Black (Trial median 8.9%,
Census: 12.7%, HF population: 22.4%), Hispanic/Latinx (Trial median 6.9%,
Census:18.3%, HF population: 15.8%), and Asian subjects (Trial median: 3.0%,
Census proportion: 5.6%) (Figure 1).

U.S. Census and HF Proportions Comparison
In pooled analysis of trials reporting White, Black, Hispanic/Latinx, and
Asian participation respectively, 77.8% (248,321/319,070) of subjects were
White, 12.3% (n = 29,353 of 239,192) of subjects were Black, 11.0%
(8,374/76,099) of subjects were Hispanic, and 9.7% (15,063/155,577) of subjects
were Asian. With exclusion of the ALLHAT trial, a marked outlier in Black subject
enrollment, just 9.1% of participants were Black. Pooled race/ethnicity specific
trial proportions were significantly different from Census and HF population
proportion estimates (p < 0.0001 for all). Stratification by intervention type
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demonstrated that no device trials referenced in the guidelines report Asian race
or Hispanic ethnicity, and just a single trial reported Black race (Figure 2).

Figure 1. Clinical trial reporting and enrollment of racial/ethnic groups.

Percent of subjects enrolled from each racial/ethnic group in trials reporting any race/ethnicity of
subjects. Black line – indicates the median. Red line – indicates Census estimate of population
proportion of each racial/ethnic group. Blue line – indicates estimate of heart failure population
proportion of each racial/ethnic group. The upper and lower bounds of boxes indicate the 75th
and 25th percentiles; whiskers represent the 97.5th and 2.5th percentiles; asterisks indicate
outliers beyond the bounds of the whiskers. The width of boxes indicates the relative number of
included trials.
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Figure 2. Percent of trials reporting each racial/ethnic subgroup stratified by the type of
intervention
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DISCUSSION
Our study aimed to examine the extent of reporting and representation of
racial/ethnic minority groups in high-impact HF clinical trials used to establish
clinical practice guidelines. Among trials included in the 2013 and 2017
ACC/AHA HF guidelines, we found infrequent, heterogenous reporting of
race/ethnicity of study participants. Black and Hispanic/Latinx participants were
significantly underrepresented in trial populations based on US Census and HF
prevalence proportion estimates. This data reflects the general
underrepresentation of racial/ethnic minority groups in high impact clinical trials
found in other studies.9,12,13 Additionally, it suggests the need for diversity
enrollment targets for clinical trials as emphasized by the FDA and NIH.8,14
Adequate reporting of racial/ethnic group representation in clinical trials is
of paramount importance to evaluate the generalizability of trial results and
assess recruitment gaps. For trials used to establish the standard of clinical
practice via guidelines, appropriate reporting is especially consequential. A
review of enrollment in recent (2001 to 2016) HF clinical trials with more than 400
subjects found that race/ethnicity was reported in only 55% of trials. 7 However,
there has been no evaluation of the representation and reporting of racial/ethnic
minority groups in HF clinical trials cited in HF guidelines. We now show that
high-impact clinical trials used to inform treatment practices through inclusion in
the 2013 and 2017 ACC/AHA guidelines have lower rates of reporting.
Among trials reporting their enrollment, Black and Hispanic participants
were significantly underrepresented. Trial underrepresentation affects
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generalizability and may exacerbate racial/ethnic disparities. Disproportionate
enrollment by race/ethnicity requires extrapolation of trial results to
underrepresented populations despite baseline HF risk factor differences (such
as hypertension) that may contribute to disproportionate HF risk, and social,
cultural, and environmental differences that may inform outcomes.
The foundational Studies of Left Ventricular Dysfunction (SOLVD) trial
evaluating enalapril versus placebo did not demonstrate equivalent effects in
African American participants compared with White participants; and isosorbide
dinitrate/hydralazine remains a Class I ACC/AHA HF recommendation for selfdescribed Black patients based on a dedicated trial.3 While guideline-directed HF
therapy should be used consistently across groups for outcome benefit, ensuring
broad efficacy through adequate trial representation may be an important link in
addressing HF health disparities.
Our study was subject to several limitations which should be noted. A lack
of standardized categories of racial/ethnic groups for reporting in the trials
resulted in the inclusion of subjects with (“non-Hispanic”) or without an indicated
ethnicity (i.e. “White” or “Black”) into the White and Black race categories.
Although the effects of this decision on the study results should be minor, there is
the possibility for some discrepancies. The inclusion of publications from 1950 to
2018 was based on the range of trials cited in the ACC/AHA guidelines. This
broad range allowed for the inclusion of older trials that were not conducted in a
period where racial/ethnic reporting was considered beneficial. However,
because these select trials are still cited in contemporary HF guidelines, their
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influence on clinical practice continues. Therefore, we believed that the inclusion
of these trials was relevant for the aims of this study. Despite these limitations,
we are confident in our results and expect that future studies would find similar
results.
To address the lack of standardized reporting of racial/ethnic categories in
HF trials and clinical trials in general, we propose that all clinical trials registered
in the U.S. be required to report the same set of racial categories (White,
Black/African American, Asian, Native American, Pacific Islander, etc.). Hispanic
ethnicity reporting should also be required, however, a more descriptive and
inclusive categorization of Hispanic ethnicity should be included to reflect the
diverse subgroups that identify as Hispanic.
In conclusion, we found significant underreporting and
underrepresentation of major racial/ethnic groups in guideline-informing HF
clinical trials, which may affect trial generalizability, be reflective of contemporary
structural bias, and should spur enduring efforts to standardize reporting and
correct underlying barriers to diverse trial enrollment.

11

WORKS CITED
1.

Bahrami H, Kronmal R, Bluemke DA, et al. Differences in the incidence of
congestive heart failure by ethnicity: the multi-ethnic study of
atherosclerosis. Arch Intern Med. 2008;168(19):2138-2145.
doi:10.1001/archinte.168.19.2138

2.

Yancy Clyde W., Jessup Mariell, Bozkurt Biykem, et al. 2013 ACCF/AHA
Guideline for the Management of Heart Failure: Executive Summary.
Circulation. 2013;128(16):1810-1852.
doi:10.1161/CIR.0b013e31829e8807

3.

Carnethon Mercedes R., Pu Jia, Howard George, et al. Cardiovascular
Health in African Americans: A Scientific Statement From the American
Heart Association. Circulation. 2017;136(21):e393-e423.
doi:10.1161/CIR.0000000000000534

4.

Yancy Clyde W., Jessup Mariell, Bozkurt Biykem, et al. 2017
ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for
the Management of Heart Failure: A Report of the American College of
Cardiology/American Heart Association Task Force on Clinical Practice
Guidelines and the Heart Failure Society of America. Circulation.
2017;136(6):e137-e161. doi:10.1161/CIR.0000000000000509

5.

Nayak A, Hicks AJ, Morris AA. Understanding the Complexity of Heart
Failure Risk and Treatment in Black Patients. Circ Heart Fail.
2020;13(8):e007264. doi:10.1161/CIRCHEARTFAILURE.120.007264

6.

Virani SS, Alonso A, Benjamin EJ, et al. Heart Disease and Stroke
Statistics-2020 Update: A Report From the American Heart
Association. Circulation. 2020;141(9):e139-e596.
doi:10.1161/CIR.0000000000000757

7.

Bahrami H, Kronmal R, Bluemke DA, et al. Differences in the incidence of
congestive heart failure by ethnicity: the multi-ethnic study of
atherosclerosis. Arch Intern Med. 2008;168(19):2138-2145.
doi:10.1001/archinte.168.19.2138

8.

Coakley M, Fadiran EO, Parrish LJ, Griffith RA, Weiss E, Carter C.
Dialogues on diversifying clinical trials: successful strategies for engaging
women and minorities in clinical trials. J Womens Health (Larchmt).
2012;21(7):713-716. doi:10.1089/jwh.2012.3733

9.

Tahhan AS, Vaduganathan M, Greene SJ, et al. Enrollment of Older
Patients, Women, and Racial and Ethnic Minorities in Contemporary Heart

12

Failure Clinical Trials: A Systematic Review. JAMA Cardiol.
2018;3(10):1011-1019. doi:10.1001/jamacardio.2018.2559
10.

Taylor, A. L., Ziesche, S., Yancy, C., Carson, P., D'Agostino, R., Jr,
Ferdinand, K., Taylor, M., Adams, K., Sabolinski, M., Worcel, M., Cohn, J.
N., & African-American Heart Failure Trial Investigators (2004).
Combination of isosorbide dinitrate and hydralazine in blacks with heart
failure. The New England journal of medicine, 351(20), 2049–2057.
https://doi.org/10.1056/NEJMoa042934

11.

Standards for maintaining, collecting, and presenting federal data on race
and ethnicity. Fed Regist. 2016.

12.

Sarraju A, Maron DJ, Rodriguez F. Under-Reporting and UnderRepresentation of Racial/Ethnic Minorities in Major Atrial Fibrillation
Clinical Trials. JACC Clin Electrophysiol. 2020;6(6):739-741.
doi:10.1016/j.jacep.2020.03.001

13.

Flores LE, Frontera WR, Andrasik MP, et al. Assessment of the Inclusion
of Racial/Ethnic Minority, Female, and Older Individuals in Vaccine Clinical
Trials. JAMA Netw Open. 2021;4(2):e2037640. Published 2021 Feb 1.
doi:10.1001/jamanetworkopen.2020.37640

14.

National Institutes of Health, (U. S. ). Outreach notebook for the NIH
guidelines on inclusion of women and minorities as subjects in clinical
research. The Institutes, Bethesda, Md.?; 1994. https://search-lib-byuedu.erl.lib.byu.edu/byu/record/cat.1820982.

13

